424 F.3d 1347 (Fed. Cir. 2005), 04-1581, Novo Nordisk Pharmaceuticals, Inc. v. Bio-Technology General Corp.

Citation: 424 F.3d 1347

Party Name: NOVO NORDISK PHARMACEUTICALS, INC. and Novo Nordisk A/S, Plaintiffs-Appellants, v. BIO-TECHNOLOGY GENERAL CORP. and Teva Pharmaceuticals USA, Inc., Defendants-Appellees.

Case Date: October 05, 2005

Court: U.S. Court of Appeals — Federal Circuit

Linked as:

Document options

Printable page
Email this

Extract

424 F.3d 1347 (Fed. Cir. 2005), 04-1581, Novo Nordisk Pharmaceuticals, Inc. v. Bio-Technology General Corp.

No longer available (Autolink)

See the full content of this document

This document cites

US Code - 35 U.S.C. § 102 Conditions For Patentability; Novelty
US Code - 35 U.S.C. § 103 Conditions For Patentability; Non-Obvious Subject Matter
US Code - 35 U.S.C. § 112 Specification
US Code - 35 U.S.C. § 146 Civil Action In Case of Derivation Proceeding
Code of Federal Regulations - Duty to disclose information material to patentability

See all quotations